A newer drug called Nexavar, used for the treatment of hepatocellular carcinoma cancer, is being marketed by Bayer and Onyx Pharmaceuticals in Europe to be approved for an officially-sanctioned treatment of liver cancer.Although Nexavar is being used in 50 countries for kidney cancer, the drug is now being described as a possible treatment for advanced liver cancer, it is now being suggested by both pharmaceutical companies for the treatment of liver cancer in Europe, with an application as a supplemental new drug being sent to the FDA sometime this summer, according to reports.
The summary phase 3 trial data concluded that Nexavar extended overall survival by 44 percent in patients with hepatocellular carcinoma compared to a placebo treatment. In addition, no additional side effects were noticed between Nexavar and placebo treatment patients.
